Peter Weeke

2.1k total citations · 2 hit papers
23 papers, 694 citations indexed

About

Peter Weeke is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Peter Weeke has authored 23 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 9 papers in Molecular Biology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Peter Weeke's work include Cardiac electrophysiology and arrhythmias (7 papers), Diabetes Treatment and Management (5 papers) and Cardiomyopathy and Myosin Studies (4 papers). Peter Weeke is often cited by papers focused on Cardiac electrophysiology and arrhythmias (7 papers), Diabetes Treatment and Management (5 papers) and Cardiomyopathy and Myosin Studies (4 papers). Peter Weeke collaborates with scholars based in United States, Denmark and United Kingdom. Peter Weeke's co-authors include Dan M. Roden, Jonathan D. Mosley, Christian M. Shaffer, Joshua C. Denny, Quinn S. Wells, Jacob Tfelt‐Hansen, Jason H. Karnes, John Deanfield, Henning Bundgaard and Ildiko Lingvay and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Peter Weeke

22 papers receiving 679 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

2024 123 citations Mikhail Kosiborod, John Deanfield et al. The Lancet profile →
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

2024 100 citations John Deanfield, Subodh Verma et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Weeke United States	14	356	217	175	106	100	23	694
Michael Krekler Germany	15	263 0.7×	163 0.8×	415 2.4×	161 1.5×	193 1.9×	20	879
Alan Yean Yip Fong Malaysia	15	350 1.0×	131 0.6×	60 0.3×	53 0.5×	106 1.1×	78	659
Hernan Rincon-Choles United States	11	121 0.3×	154 0.7×	111 0.6×	75 0.7×	95 0.9×	22	625
Yining Yang China	13	169 0.5×	111 0.5×	83 0.5×	65 0.6×	80 0.8×	48	570
J E Sealey United States	13	669 1.9×	192 0.9×	316 1.8×	90 0.8×	99 1.0×	16	1.0k
Russell Esterline United States	15	66 0.2×	214 1.0×	282 1.6×	94 0.9×	153 1.5×	26	589
Ryu Kobayashi Japan	15	227 0.6×	125 0.6×	162 0.9×	72 0.7×	81 0.8×	42	521
Fuki Ikeda Japan	15	227 0.6×	249 1.1×	284 1.6×	136 1.3×	216 2.2×	38	753
David J. Kazierad United States	14	166 0.5×	136 0.6×	192 1.1×	53 0.5×	108 1.1×	27	560
Amir F. Ayyobi Canada	11	247 0.7×	170 0.8×	482 2.8×	89 0.8×	342 3.4×	17	789

Countries citing papers authored by Peter Weeke

Since Specialization

Citations

This map shows the geographic impact of Peter Weeke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Weeke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Weeke more than expected).

Fields of papers citing papers by Peter Weeke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Weeke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Weeke. The network helps show where Peter Weeke may publish in the future.

Co-authorship network of co-authors of Peter Weeke

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Weeke. A scholar is included among the top collaborators of Peter Weeke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Weeke. Peter Weeke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Colhoun, Helen M., Scott S. Emerson, G. Kees Hovingh, et al.. (2025). EFFECT OF THE GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON TOTAL CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY BUT NO DIABETES IN THE SELECT TRIAL. Journal of the American College of Cardiology. 85(12). 378–378.

Morin, M., Benjamin M. Scirica, Helen M. Colhoun, et al.. (2024). The Effect of Semaglutide on Mortality and COVID-19-related Deaths — A Pre-specified Analysis From the SELECT Trial. Canadian Journal of Diabetes. 48(7). S6–S6. 1 indexed citations

Verma, Subodh, Scott S. Emerson, Jorge Plutzky, et al.. (2024). Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity. Journal of the American College of Cardiology. 85(5). 541–545. 7 indexed citations

Deanfield, John, Subodh Verma, Benjamin M. Scirica, et al.. (2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet. 404(10454). 773–786. 100 indexed citations breakdown →

Kosiborod, Mikhail, John Deanfield, Richard Pratley, et al.. (2024). Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. The Lancet. 404(10456). 949–961. 123 indexed citations breakdown →

Garcia, Rodrigue, Christoffer Rasmus Vissing, Peter Weeke, et al.. (2022). Ethnic disparities in out-of-hospital cardiac arrest: A population-based cohort study among adult Danish immigrants. The Lancet Regional Health - Europe. 22. 100477–100477. 11 indexed citations

Weeke, Peter, et al.. (2019). Pharmacokinetic variability of beta‐adrenergic blocking agents used in cardiology. Pharmacology Research & Perspectives. 7(4). e00496–e00496. 36 indexed citations

Ahlberg, Gustav, Jonas Ghouse, Charlotte Andreasen, et al.. (2016). Analyses of more than 60,000 exomes questions the role of numerous genes previously associated with dilated cardiomyopathy. Molecular Genetics & Genomic Medicine. 4(6). 617–623. 22 indexed citations

McGeachie, Michael J., Ann Chen Wu, Sze Man Tse, et al.. (2015). CTNNA3 and SEMA3D: Promising loci for asthma exacerbation identified through multiple genome-wide association studies. Journal of Allergy and Clinical Immunology. 136(6). 1503–1510. 34 indexed citations

10.

HERTZ, CHRISTIN L., Sofie Lindgren Christiansen, Laura Ferrero‐Miliani, et al.. (2015). Next-generation sequencing of 100 candidate genes in young victims of suspected sudden cardiac death with structural abnormalities of the heart. International Journal of Legal Medicine. 130(1). 91–102. 44 indexed citations

11.

Savio‐Galimberti, Eleonora, Peter Weeke, Raafia Muhammad, et al.. (2014). SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. Cardiovascular Research. 104(2). 355–363. 52 indexed citations

12.

Karnes, Jason H., Robert M. Cronin, Jérôme Rollin, et al.. (2014). A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record. Thrombosis and Haemostasis. 113(4). 772–781. 42 indexed citations

13.

Weeke, Peter, Raafia Muhammad, Jessica Delaney, et al.. (2014). Whole-exome sequencing in familial atrial fibrillation. European Heart Journal. 35(36). 2477–2483. 31 indexed citations

14.

Mosley, Jonathan D., Sara L. Van Driest, Peter Weeke, et al.. (2014). Integrating EMR-Linked and In Vivo Functional Genetic Data to Identify New Genotype-Phenotype Associations. PLoS ONE. 9(6). e100322–e100322. 3 indexed citations

15.

Weeke, Peter, Jonathan D. Mosley, D. Hanna, et al.. (2014). Exome Sequencing Implicates an Increased Burden of Rare Potassium Channel Variants in the Risk of Drug-Induced Long QT Interval Syndrome. Journal of the American College of Cardiology. 63(14). 1430–1437. 52 indexed citations

16.

Weeke, Peter & Dan M. Roden. (2013). Pharmacogenomics and Cardiovascular Disease. Current Cardiology Reports. 15(7). 376–376. 8 indexed citations

17.

Karnes, Jason H., Sara L. Van Driest, Erica Bowton, et al.. (2013). Using systems approaches to address challenges for clinical implementation of pharmacogenomics. WIREs Systems Biology and Medicine. 6(2). 125–135. 16 indexed citations

18.

Weeke, Peter, Jonathan D. Mosley, D. Hanna, et al.. (2013). Abstract 11082: Exome Sequencing Implicates the Burden of Rare Potassium Channel Variants in the Risk of Drug Induced Long QT Syndrome. Circulation. 128(suppl_22). 1 indexed citations

19.

Wells, Quinn S., Jason R. Becker, Yan Ru Su, et al.. (2013). Whole Exome Sequencing Identifies a Causal RBM20 Mutation in a Large Pedigree With Familial Dilated Cardiomyopathy. Circulation Cardiovascular Genetics. 6(4). 317–326. 51 indexed citations

20.

Weeke, Peter & Dan M. Roden. (2013). Applied Pharmacogenomics in Cardiovascular Medicine. Annual Review of Medicine. 65(1). 81–94. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact